Genmab A/S Announces DuoBody Platform Collaboration With Eli Lilly and Company
Published: Jan 14, 2014
Copenhagen, Denmark; January 14, 2014 – Genmab A/S (OMX: GEN) announced today a research collaboration with Eli Lilly and Company to use and evaluate Genmab’s DuoBody technology platform for the creation of bispecific antibodies. Under the collaboration, Lilly will initially evaluate the DuoBody technology platform in house.
Help employers find you! Check out all the jobs and post your resume.